Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 3/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | LTK | P29376 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2026656 | 0.91 | CHRM1 (0.47) | GRM2FGFR1BRD4CHRM1 | |
| SCHEMBL2026378 | 0.91 | ALK (0.44) | TNKSGRM2ALKJAK2PRKD3 | |
| SCHEMBL2023271 | 0.89 | GRM2 (0.54) | TNKSGRM2ALKJAK2PRKD3 | |
| SCHEMBL2026458 | 0.83 | TNKS (0.43) | TNKSALKRETMETFLT3 | |
| SCHEMBL2024030 | 0.82 | CHRM1 (0.45) | GRM2ALKKDRPIK3CGCHRM1 | |
| SCHEMBL2023961 | 0.79 | GRM2 (0.43) | GRM2BRD4PIK3CG | |
| SCHEMBL2028364 | 0.78 | HDAC4 (0.45) | GRM2ABL1BRD4PIK3CG | |
| SCHEMBL1001737 | 0.76 | GRM2 (0.57) | GRM2ABL1PIK3CGHTR6 | |
| SCHEMBL2024045 | 0.75 | GRM2 (0.41) | GRM2PIK3CGCHRM1 | |
| SCHEMBL2024082 | 0.74 | TNKS (0.43) | TNKSGRM2ALKJAK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | TNKS 3673/4885GRM2 4/4885ALK 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.